Liu Y, Liang J, Zhu R, Yang Y, Wang Y, Wei W
Acta Mater Med. 2024; 3(1):72-87.
PMID: 39373008
PMC: 11452161.
DOI: 10.15212/amm-2024-0010.
Taylor J, Barrett N, Martinez Cuesta S, Cassidy K, Pachl F, Dodgson J
Commun Biol. 2024; 7(1):1179.
PMID: 39300128
PMC: 11415077.
DOI: 10.1038/s42003-024-06803-4.
Tang K, Wang S, Feng S, Yang X, Guo Y, Ren X
Acta Pharm Sin B. 2024; 14(8):3624-3642.
PMID: 39234614
PMC: 11372460.
DOI: 10.1016/j.apsb.2024.03.028.
Wang A, Zhang Y, Lv X, Liang G
Acta Pharm Sin B. 2024; 14(8):3295-3311.
PMID: 39220870
PMC: 11365412.
DOI: 10.1016/j.apsb.2024.05.006.
Kamaraj R, Ghosh S, Das S, Sen S, Kumar P, Majumdar M
Bioconjug Chem. 2024; 35(8):1089-1115.
PMID: 38990186
PMC: 11342303.
DOI: 10.1021/acs.bioconjchem.4c00253.
Self-Assembled Matrine-PROTAC Encapsulating Zinc(II) Phthalocyanine with GSH-Depletion-Enhanced ROS Generation for Cancer Therapy.
Lai S, Wang B, Sun K, Li F, Liu Q, Yu X
Molecules. 2024; 29(8).
PMID: 38675664
PMC: 11054886.
DOI: 10.3390/molecules29081845.
Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation.
Miao J, Zhang Z
ChemMedChem. 2024; 19(7):e202300669.
PMID: 38233347
PMC: 11021144.
DOI: 10.1002/cmdc.202300669.
Binding Free Energy Calculation Based on the Fragment Molecular Orbital Method and Its Application in Designing Novel SHP-2 Allosteric Inhibitors.
Yuan Z, Chen X, Fan S, Chang L, Chu L, Zhang Y
Int J Mol Sci. 2024; 25(1).
PMID: 38203841
PMC: 10779950.
DOI: 10.3390/ijms25010671.
Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity.
Miao J, Bai Y, Miao Y, Qu Z, Dong J, Zhang R
Molecules. 2023; 28(19).
PMID: 37836790
PMC: 10574094.
DOI: 10.3390/molecules28196947.
Setting sail: Maneuvering SHP2 activity and its effects in cancer.
Welsh C, Allen S, Madan L
Adv Cancer Res. 2023; 160:17-60.
PMID: 37704288
PMC: 10500121.
DOI: 10.1016/bs.acr.2023.03.003.
SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment.
Sodir N, Pathria G, Adamkewicz J, Kelley E, Sudhamsu J, Merchant M
Cancer Discov. 2023; 13(11):2339-2355.
PMID: 37682219
PMC: 10618746.
DOI: 10.1158/2159-8290.CD-23-0383.
Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
Xie X, Yu T, Li X, Zhang N, Foster L, Peng C
Signal Transduct Target Ther. 2023; 8(1):335.
PMID: 37669923
PMC: 10480221.
DOI: 10.1038/s41392-023-01589-z.
Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer.
Lu Y, Yang Y, Zhu G, Zeng H, Fan Y, Guo F
Int J Biol Sci. 2023; 19(11):3360-3382.
PMID: 37496997
PMC: 10367563.
DOI: 10.7150/ijbs.83026.
PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy.
Kelm J, Pandey D, Malin E, Kansou H, Arora S, Kumar R
Mol Cancer. 2023; 22(1):62.
PMID: 36991452
PMC: 10061819.
DOI: 10.1186/s12943-022-01707-5.
Small-Molecule PROTACs for Cancer Immunotherapy.
Liu Z, Zhang Y, Xiang Y, Kang X
Molecules. 2022; 27(17).
PMID: 36080223
PMC: 9458232.
DOI: 10.3390/molecules27175439.
A comprehensive review of SHP2 and its role in cancer.
Asmamaw M, Shi X, Zhang L, Liu H
Cell Oncol (Dordr). 2022; 45(5):729-753.
PMID: 36066752
DOI: 10.1007/s13402-022-00698-1.
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).
He M, Cao C, Ni Z, Liu Y, Song P, Hao S
Signal Transduct Target Ther. 2022; 7(1):181.
PMID: 35680848
PMC: 9178337.
DOI: 10.1038/s41392-022-00999-9.
Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy.
Pan J, Zhou L, Zhang C, Xu Q, Sun Y
Signal Transduct Target Ther. 2022; 7(1):177.
PMID: 35665742
PMC: 9166240.
DOI: 10.1038/s41392-022-01038-3.
Oxidative stress promotes fibrosis in systemic sclerosis through stabilization of a kinase-phosphatase complex.
Zhang R, Kumar G, Hansen U, Zoccheddu M, Sacchetti C, Holmes Z
JCI Insight. 2022; 7(8).
PMID: 35451370
PMC: 9089796.
DOI: 10.1172/jci.insight.155761.
Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1.
Deng Y, Ma G, Vallega K, Wang D, Wang M, Wang C
Cancer Gene Ther. 2022; 29(11):1558-1569.
PMID: 35449204
DOI: 10.1038/s41417-022-00472-3.